Atara Biotherapeutics (ATRA) Rating Lowered to Hold at ValuEngine

Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Friday, ValuEngine reports.

Several other equities research analysts have also issued reports on the company. Mizuho started coverage on Atara Biotherapeutics in a research report on Tuesday, January 22nd. They set a “buy” rating and a $62.00 target price for the company. William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a research report on Monday, April 1st. BidaskClub lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Friday, February 22nd. Cowen reissued a “buy” rating on shares of Atara Biotherapeutics in a report on Tuesday, February 26th. Finally, Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 4th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $43.33.

Shares of Atara Biotherapeutics stock opened at $23.99 on Friday. Atara Biotherapeutics has a 1 year low of $23.58 and a 1 year high of $54.45. The firm has a market cap of $1.12 billion, a PE ratio of -4.55 and a beta of 2.11. The company has a quick ratio of 9.96, a current ratio of 9.96 and a debt-to-equity ratio of 0.05.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.48) by $0.04. Equities analysts expect that Atara Biotherapeutics will post -5.69 earnings per share for the current fiscal year.

In related news, CEO Isaac E. Ciechanover sold 7,800 shares of Atara Biotherapeutics stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $36.14, for a total value of $281,892.00. Following the completion of the sale, the chief executive officer now owns 332,243 shares of the company’s stock, valued at approximately $12,007,262.02. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Joe Newell sold 1,500 shares of Atara Biotherapeutics stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $36.13, for a total value of $54,195.00. Following the completion of the sale, the insider now directly owns 48,646 shares of the company’s stock, valued at approximately $1,757,579.98. The disclosure for this sale can be found here. In the last three months, insiders sold 129,990 shares of company stock valued at $4,678,666. 10.60% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of the business. FMR LLC grew its holdings in Atara Biotherapeutics by 21.7% during the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock valued at $255,114,000 after buying an additional 1,143,787 shares in the last quarter. BlackRock Inc. grew its holdings in Atara Biotherapeutics by 0.6% during the 4th quarter. BlackRock Inc. now owns 3,513,235 shares of the biotechnology company’s stock valued at $122,050,000 after buying an additional 22,453 shares in the last quarter. Vanguard Group Inc. grew its holdings in Atara Biotherapeutics by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,487,567 shares of the biotechnology company’s stock valued at $102,861,000 after buying an additional 106,213 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Atara Biotherapeutics by 53.8% during the 1st quarter. JPMorgan Chase & Co. now owns 1,917,903 shares of the biotechnology company’s stock valued at $76,237,000 after buying an additional 671,216 shares in the last quarter. Finally, Neuberger Berman Group LLC grew its holdings in Atara Biotherapeutics by 1.3% during the 1st quarter. Neuberger Berman Group LLC now owns 1,306,651 shares of the biotechnology company’s stock valued at $51,939,000 after buying an additional 16,703 shares in the last quarter.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Recommended Story: What are municipal bonds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.